Loading company…
Shanghai MicroPort CardioFlow Medtech develops structural heart devices, including the VitaFlow transcatheter aortic valve.
Established in 2015 and based in Shanghai, China, the company holds a High-Tech Enterprise Certificate and focuses on heart valve products. Its main product, the VitaFlow transcatheter aortic valve and delivery system, treats severe calcific aortic valve stenosis. In January 2021 it raised CNY 809.5 million in pre-IPO funding from CPE Funds Management, Hillhouse Capital, Lake Bleu Capital and 3W Fund Management, and listed on the Hong Kong Stock Exchange in February 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in